Roger Williams, Vice President of Commercial APAC at Certara said, “Together, A2 Healthcare and Certara provide even greater access to Certara’s drug development software and services in Japan, enabling researchers to make critical decisions with greater certainty.”
“A2 Healthcare is committed to providing our customers with the best modeling and simulation and regulatory solutions to move their important research forward,” said Yukawa Tomohito, Deputy Executive Director, Data Science Division at A2 Healthcare. “While we both have extensive experience in pharmacometrics, Certara advances our capabilities and helps broaden our scientific portfolio. This partnership will help our clients accelerate the delivery of new, novel medicines to patients.”
关于Certara
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.
About A2Healthcare
A2 is one of the industry’s leading CROs (Contract Research Organizations), conducting clinical trials under contract from pharmaceutical companies, and has been involved in the development of numerous drugs with approximately 1,300 employees in Tokyo, Osaka, Taiwan, and Boston. In addition to the traditional lifestyle-related disease area, A2 in the development of drugs related to cancer, central nervous system, respiratory disease, vaccine, and also promotes the introduction of various advanced solutions such as RBM, eSource Data, eSubmission, and DCT (Decentralized Clinical Trials) to improve the efficiency of clinical trials. A2Healthcare is also a subsidiary of ITOCHU Corporation and forms the core of the group’s healthcare business. A2 Healthcare Corporation: http://www.a2healthcare.com/en
